Inclusion Criteria:

• Healthy adult male or female volunteers, 18-45 years of agestart of the study.
• Other birth control methods may be deemed acceptable
• Postmenopausal women with amenorrhea for at least 2 years will be eligible
• Voluntarily consent to participate in the study

Exclusion Criteria:

• History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease

• In addition, history or presence of:

  • alcoholism or drug abuse within the past year
  • hypersensitivity or idiosyncratic reaction to Loratadine or any other H1-receptor antagonist
  • hypersensitivity or idiosyncratic reaction to Pseudoephedrine or any other sympathomimetic amines
• Glaucoma or hypermetropia
• Subjects receiving a monoamine oxidase (MAO) inhibitor or within 14 days of stopping use of an MAO inhibitor, or any sympathomimetic amines
• Subjects who have used any drugs or other substances known to be strong inhibitors of CYP (cytochrome P450) enzymes within 10 days of study start
• Subjects who have used any drugs or other substances known to be strong inducers of CYP (cytochrome P450) enzymes within 28 days of study start
• Female subjects who are pregnant or lactating
• Subjects who have been on an abnormal diet (for whatever reason) during the 28 days prior to the first dose

• Subjects who, through completion of the study, would have donated in excess of:

  • 500 mL of blood in 14 days
  • 500-750 mL of blood in 14 days (unless approved by the principal Investigator)
  • 1000 mL of blood in 90 days
  • 1250 mL of blood in 120 days
  • 1500 mL of blood in 180 days
  • 2000 mL of blood in 270 days
  • 2500 mL of blood in 1 days
• Subjects who have participated in another clinical trial within 28 days prior to the study start